SHARE:  
Join Our Email List
January 11, 2023
CSL Behring Offers Copay Assistance Program For Privigen

AAIDA & IAF Advocate For A Program For Patients
AAIDA and the Infusion Access Foundation (IAF) are excited to share that as of January 3, 2023, CSL Behring began offering a copay assistance program to patients for their intravenous immunoglobulin (IVIG) drug, Privigen.

This announcement comes after AAIDA and IAF spent many months of back-and-forth discussions with CSL Behring to inform them of the importance of having a copay assistance program in place for patients. Other partner organizations signed onto a letter that supported AAIDA and IAF's advocacy efforts to create a program for patients as healthcare costs continue to rise.

CSL Behring, the manufacturer for Privigen, has been offering a copay assistance program for their subcutaneous immunoglobulin drug (SCIG), Hizentra, for over a decade but not for Privigen. Privigen is one of eleven IVIG products that is FDA approved to treat seven rare conditions while Hizentra is one of eight SCIG products available. All manufactures of these drugs now offer a copay assistance program for patients.

Thank you to all the supporters and organizations that helped AAIDA and IAF be able to achieve this much anticipated goal for patients!
Importance of Copay Assistance Programs For Chronically Ill Patients
And How Copay Accumulators Impact Patients
A recent opinion piece written by a chronically ill patient outlines the importance of having copay assistance program in place as well as establishing laws that prohibit abusive insurance tactics such as copay accumulators.

The patient states: "Through the copay accumulator adjustment program, insurance gets paid from copay assistance programs, gets their contracted rate per medication fill, and keeps getting paid upwards of five times what they should receive because my deductible never tracks."
Stay connected with AAIDA on our social media channels